Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
153 hedge funds and large institutions have $336M invested in Esperion Therapeutics in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 21 closing their positions.
135% more call options, than puts
Call options by funds: $8.22M | Put options by funds: $3.49M
105% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 21
71% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 28
56% more capital invested
Capital invested by funds: $215M → $336M (+$121M)
16% more funds holding
Funds holding: 132 → 153 (+21)
4.55% more ownership
Funds ownership: 63.26% → 67.81% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$33.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$19.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$18.5M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$13.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$9.57M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
-$8.55M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.53M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$2.95M |
| 5 |
WCM
Whitefort Capital Management
New York
|
-$2.65M |
ESPR Hedge Fund Activity: Q1 2024 in Review
153 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2024, worth a combined $336M — up 56% from $215M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new ESPR positions and 21 closed out — a net gain of 22 holders — while 48 added to existing stakes and 28 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $33.3M. The largest seller was Armistice Capital, exiting entirely with an estimated $9.57M sold.
- 153 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2024, up from 132 in Q4 2023.
- Funds reported $336M of Esperion Therapeutics stock for Q1 2024, up 56% quarter-over-quarter.
- 43 funds opened new Esperion Therapeutics positions in Q1 2024 and 21 closed out, a net change of +22 holders.
- The largest Esperion Therapeutics buyer in Q1 2024 was OrbiMed, an estimated $33.3M added.
- The largest Esperion Therapeutics seller in Q1 2024 was Armistice Capital, an estimated $9.57M sold.
Based on aggregated 13F filings for Q1 2024.